L3VLUP
ProSign in

ROIV · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ROIVJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ROIV
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterROIVJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 2020none listed holders, n.a.32 holders, $26.6bn
Q1 2021none listed holders, n.a.31 holders, $25.3bn
Q2 2021none listed holders, n.a.37 holders, $25.6bn
Q3 2021none listed holders, n.a.40 holders, $24.1bn
Q4 20211 holders, $889m33 holders, $25.2bn
Q1 20221 holders, $436m35 holders, $28.2bn
Q2 20221 holders, $359m33 holders, $26.9bn
Q3 20222 holders, $292m36 holders, $25.4bn
Q4 20223 holders, $829m35 holders, $27.6bn
Q1 20236 holders, $715m42 holders, $24.5bn
Q2 20238 holders, $1.0bn38 holders, $25.0bn
Q3 20238 holders, $1.7bn37 holders, $18.9bn
Q4 20236 holders, $1.5bn31 holders, $19.0bn
Q1 20246 holders, $912m32 holders, $19.7bn
Q2 20248 holders, $1.4bn35 holders, $20.4bn
Q3 20248 holders, $1.4bn28 holders, $22.3bn
Q4 20248 holders, $1.3bn37 holders, $20.4bn
Q1 20257 holders, $1.1bn32 holders, $20.5bn
Q2 20259 holders, $1.2bn31 holders, $18.4bn
Q3 202511 holders, $1.5bn32 holders, $23.7bn
Q4 202514 holders, $1.9bn29 holders, $27.8bn
Q1 202614 holders, $3.3bn34 holders, $35.6bn
Q2 202615 holders, $4.5bn33 holders, $39.1bn
ROIV

Roivant Sciences LTD

Holders
14
Reported value
$1.9bn
Buyers
16
Sellers
15

Breadth +1 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
29
Reported value
$27.8bn
Buyers
13
Sellers
26

Breadth -13 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 38 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ROIV (9)

Farallon Capital Management LLC, Greenlight Capital, PDT Partners LLC, Polen Capital Management LLC, Soros Fund Management LLC, Verition Fund Management LLC, Viking Global Investors LP, Voloridge Investment Management LLC, Winton Group Ltd

Only JNJ (24)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., Dodge & Cox, Element Capital Management LLC, Freestone Grove Partners LP, GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Markel Group Inc, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Rokos Capital Management LLP, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →